Core Viewpoint - The company Zejing Pharmaceutical (688266.SH) is set to present clinical research data and updates on its self-developed drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) at the European Society for Medical Oncology (ESMO) annual meeting scheduled for October 17-21, 2025 [1] Group 1: Drug Development Progress - ZG006 has demonstrated significant and durable anti-tumor efficacy in patients with advanced small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) who have failed existing standard treatments, along with good tolerability and safety [1] - ZG005, when combined with chemotherapy in patients with advanced neuroendocrine cancer, has shown good safety and tolerability, indicating promising efficacy that supports further clinical research [1]

Core Viewpoint - Zai Jian Pharmaceutical announced the clinical research data and latest progress of its self-developed drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) will be presented at the European Society for Medical Oncology (ESMO) annual meeting from October 17 to 21 [1] Group 1: Drug Development - ZG006 is a trispecific antibody drug developed through the company's dual/multi-specific antibody research platform, which has received clinical trial approval from both the US FDA and China's NMPA [1] - ZG006 has been included in the breakthrough therapy designation by the National Medical Products Administration (NMPA) and has been granted orphan drug status by the US FDA [1] - ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody classified as a category 1 innovative tumor immunotherapy biological product, expected to be used for the treatment of various solid tumors [1]

Core Viewpoint - Zai Lab's new drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) will present clinical research data at the European Society for Medical Oncology (ESMO) annual meeting from October 17 to 21, 2025, highlighting their innovative approaches in targeting DLL3 [1] Group 1: Drug Development - ZG006 is the world's first tri-specific antibody targeting DLL3 (DLL3×DLL3×CD3), representing a first-in-class molecular form with the potential to become a best-in-class molecule [1] - ZG005 is one of the first drugs to enter clinical research targeting the same mechanism, with no similar mechanism drugs approved globally [1]

Core Insights - The company Zejing Pharmaceutical announced that it will present clinical research data for its self-developed drugs Alveltamig (code: ZG006) and Nilvanstomig (code: ZG005) at the 28th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO) scheduled for September 10-14, 2025 [2] - The announcement indicates that the release of the latest clinical data will not have a significant impact on the company's recent performance [2] - The pharmaceutical industry is characterized by high technology, high risk, and high added value, with long and complex development cycles for drugs, making them susceptible to various uncertainties [2] Company Developments - The company will fulfill its information disclosure obligations based on subsequent developments related to the clinical trials [2] - The timeline for drug development from research, clinical trials, approval, to production is lengthy and involves multiple stages [2]

Core Insights - The company Zai Lab (stock code: 688266.SH) announced that clinical research data and updates for its self-developed drugs Alveltamig (code: ZG006) and Nilvanstomig (code: ZG005) will be presented at the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) from September 10 to 14, 2025 [1] Group 1: ZG006 Clinical Research - ZG006 is undergoing a Phase II dose-optimization clinical study (ZG006-002) for the treatment of refractory advanced small cell lung cancer (SCLC) patients, which has been selected for an oral presentation at the conference [1] - As of May 12, 2025, a total of 60 SCLC patients who have undergone three or more lines of treatment were randomly assigned to receive either ZG006 at 10mg Q2W or 30mg Q2W, with the initial dose being 1mg [1] - The baseline characteristics of both patient groups were generally balanced [1] Group 2: ZG005 Clinical Research - ZG005 is being evaluated in a Phase I/II clinical study (ZG005-004) for its safety, pharmacokinetics, and preliminary efficacy in combination with Etoposide and Cisplatin (EP) for first-line treatment of advanced neuroendocrine carcinoma [1] - As of August 21, 2025, a total of 84 patients have been enrolled in the study, with 92.9% of patients having a Ki-67 proliferation index of ≥55% and 64.3% of patients exhibiting liver metastasis [1] - The most common primary tumor site among patients was the gastrointestinal tract, accounting for 36.9% [1]

泽璟制药(688266.SH)发布公告，公司自主研发的新药Alveltamig(代号：ZG006)、Nilvanstomig(代号： ZG005)的临床研究数据及最新进展将于2025年9月10日至14日召开的第28届中国临床肿瘤学会(CSCO)学 术年会上发布。 ZG006单药治疗在难治性晚期小细胞肺癌患者中的II期剂量优化临床研究(ZG006-002)入选本次年会肺癌 专场口头报告。截至2025年5月12日，共60例三线及以上小细胞肺癌(SCLC)患者按1:1随机接受 ZG00610mgQ2W或30mgQ2W治疗并纳入分析。首次给药均为1mg滴定剂量。两组患者的基线特征总体 均衡。 ZG005联合依托泊苷及顺铂(EP)在一线晚期神经内分泌癌患者中的安全性、药代动力学特征及初步疗效 的I/II期临床研究(ZG005-004)数据及最新进展：截至2025年8月21日，共纳入84例患者。92.9%患者Ki- 67增殖指数≥55%，64.3%的患者存在肝转移。最常见的原发肿瘤部位为胃肠道，占36.9%。 ...